Sangamo Therapeutics, Inc. (SGMO): Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization

Corporate emblem and logo of Sangamo BioSciences (SGMO)

Sangamo Therapeutics (SGMO) monetizes its DNA design developments through licensing agreements with pharma behemoths, which eliminates capital expenditures for production. This chart of the share price on GURU.Markets shows that the EV/EBITDA is 0.00. Business efficiency is driven by the external execution of clinical orders, while the unique gene therapy environment promises to transform treatment methods for hereditary pathologies.

SGMO Sangamo BioSciences: Company Value to EBITDA in the range 11/23/2025 - 05/09/2026

Analytical breakdowns for Sangamo Therapeutics, Inc. (SGMO)

- current price and projected stock value:
Summary company analysis:Sangamo Therapeutics Inc. SGMO
Manufactured products of sangamo.com

Prolonged clinical trial cycles and patent restrictions at Sangamo Therapeutics (SGMO) require significant capital expenditures. The business's EV/EBITDA multiple history compares the total enterprise value, including debt load, with its operating profitability before taxes. This chart reflects the market's assessment of the company's ability to generate revenue amidst high regulatory barriers. Investors utilize this indicator to determine the fair value of assets given the high level of leveraged capital.

Competitor analysis

Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|qiagen.com (QGEN) - Company Value to EBITDA|IONS: Enterprise Value to EBITDA Ratio|Enterprise Value to EBITDA Multiple Repligen (RGEN)|RNA (Avidity) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics AG - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization GeneDx Holdings|Enterprise Value to Operating Income Before Depreciation RARE (Ultragenyx)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics (BEAM)|Enterprise Value to Operating Income Before Depreciation Ratio SRPT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Twist Bioscience Corp TWST|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics, Inc. (TXG)|Intellia Therapeutics - EV/EBITDA Multiple|STOK - EV/EBITDA Multiple|BLFS (biolifesolutions.com) - Enterprise Value to EBITDA Ratio|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio MAZE|Sionna Pharma - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PRME|TSHA (Taysha Gene Therapies) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO Inc - EV/EBITDA Multiple|Company Value to EBITDA Solid Corp|Ocugen (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Pacific Biosciences|Enterprise Value to EBITDA Ratio BNTC|Enterprise Value to EBITDA Ratio Design Therapeutics Inc (DSGN)|EV/EBITDA Multiple RCKT|EV/EBITDA Multiple 4D Molecular Therapeutics, Inc. (FDMT)|lexeotx.com - Enterprise Value to EBITDA Ratio|KRRO: Enterprise Value to Operating Income Before Depreciation|Editas Corp - EV/EBITDA Multiple|SLN: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|PRQR (ProQR) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc